Kadcyla Significantly Extends PFS in Advanced HER2-Positive Breast Cancer
Results of the phase 3 TH3RESA trial presented at ECC 2013 have found Kadcyla extends progression-free survival compared to physician’s choice.
All articles by Traci Dantoni
Perjeta Granted Accelerated Approval for Neoadjuvant Breast Cancer
The FDA today granted accelerated approval to Perjeta® (pertuzumab) as part of a treatment regimen for patients with high-risk, HER2-positive, early-stage breast cancer.
How Will the BRCA Patent Ruling Affect Oncology?
The Supreme Court ruling last week that human genes cannot be patented will lower the cost of BRCA gene tests and open doors to research.
Adjuvant Bevacizumab Well-Tolerated in Patients with Melanoma at High Risk of Recurrence
In patients with melaoma at high risk of recurrence, adjuvant bevacizumab is well tolerated and improves the disease-free interval, found research presented at ASCO 2013.
Proton Beam Therapy with Intra-arterial Infusion Chemotherapy Safe, Effective for Locally Advanced Tongue Cancer
When combined with selective IACT, proton beam therapy appears to be as safe and effective as surgery in treating locally advanced tongue cancer, found research presented at ASCO 2013.
ASH: Pomalidomide Plus Low-dose Dexamethasone Effective, Tolerable in Refractory Myeloma
Pomalidomide (POM) plus low-dose dexamethasone (LoDex) shows promise as a treatment for relapsed and refractory multiple myeloma (RRMM), according to an analysis of data from a phase 2 safety and efficacy trial presented during the 54th American Society of Hematology Annual Meeting and Exposition.
ASH: First Int’l Good Clinical Practice Guidelines for Use of Antithrombotics
Global experts called on colleagues attending the 54th American Society of Hematology Annual Meeting and Exposition to help disseminate and implement the first International Good Clinical Practice Guidelines for the use of antithrombotics.
- Loading...
Loading...
Loading... 
Loading...